Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, internati
The demonstration of statistically significant and clinically meaningful benefit of evenamide, a glutamate modulator, as add-on treatment in patients with chronic schizophrenia inadequately responding to their second-generation antipsychotic may represent a new treatment paradigm for this population.
Authors
- Richard D. Hartman (ORCID: https://orcid.org/0000-0002-3078-3814)
- Alessio Turolla
- Arjun Roy
- Ravi Anand (ORCID: https://orcid.org/0000-0001-7973-9913)
- Giovanni Chinellato (ORCID: https://orcid.org/0009-0001-7091-8672)
- F. Sansi
Institutions
- CliniRx (India) (IN)
- Applied Pharma Research (Switzerland) (CH)
- Newron Pharmaceuticals (Italy) (IT)
Publication Details
- Journal
- Neuropharmacology
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1016/j.neuropharm.2024.110275
- Citations
- 10
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.86